Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

GORE Embolic Protection With Reverse Flow (EMPiRE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00594100
Recruitment Status : Completed
First Posted : January 15, 2008
Results First Posted : May 5, 2009
Last Update Posted : December 27, 2013
Information provided by (Responsible Party):
W.L.Gore & Associates

Brief Summary:
To compare the 30-day safety and efficacy of the GORE Flow Reversal System when used with approved carotid stents to an Objective Performance Criterion derived from distal embolic protection studies.

Condition or disease Intervention/treatment Phase
Carotid Artery Stenosis Device: GORE Flow Reversal System (GFRS) Phase 3

Detailed Description:

The GORE Flow Reversal System, manufactured by W. L. Gore & Associates, Inc., was developed as a proximal occlusion device to reverse the flow of blood in the carotid artery. It is designed to achieve embolic protection prior to crossing the lesion in the majority of cases in order to minimize the possibility of an adverse event occurrence.

The objective of this study is to assess the safety and effectiveness of the GORE Flow Reversal System when used to provide embolic protection during Carotid Artery Stent (CAS) procedures. Subjects diagnosed with carotid stenosis requiring revascularization and are at high risk for adverse events from CEA are eligible to participate.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 245 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Embolic Protection With Reverse Flow Study of the GORE Neuro Protection System in Carotid Stenting of Subjects At High Risk for Carotid Endarterectomy
Study Start Date : July 2006
Actual Primary Completion Date : September 2008
Actual Study Completion Date : September 2008

Arm Intervention/treatment
Experimental: GFRS Pivotal Subjects
All non-training subjects using the GORE Flow Reversal System for embolic protection during carotid artery stenting (all subjects other than first two subjects accounted for in Training Cases).
Device: GORE Flow Reversal System (GFRS)
Carotid artery angioplasty and stenting with embolic protection
Other Name: Gore Neuro Protection System

Primary Outcome Measures :
  1. Composite Major Adverse Event (MAE) Rate [ Time Frame: Treatment through 30-day visit window ]
    Number of participants with one or more Major Adverse Event (death, stroke, myocardial infarction, and/or transient ischemic attack (TIA)) through the 30-day follow-up (non-hierarchical; MAE adjudicated by independent Clinical Events Committee)

Secondary Outcome Measures :
  1. Flow Reversal System Technical Success [ Time Frame: Procedure ]
    Number of participants with Technical Success using the GORE Flow Reversal System (system deployed and utilized during stenting procedure)

  2. Flow Reversal System Success [ Time Frame: Procedure ]
    Number of participants where the GORE Flow Reversal System was delivered, placed, reverse flow was established, and the balloon sheath and wire retrieved as outlined in the Instructions for Use without causing any adverse events during the procedure.

  3. Stent Success [ Time Frame: Procedure ]
    Number of participants where the FDA-approved stent was successfully delivered, deployed,and delivery system removed with an attainment of < 50% residual stenosis following stent placement, as assessed by the angiographic core laboratory.

  4. Clinical Success [ Time Frame: 24-48 Hours Post-Procedure ]
    Number of participants with Flow Reversal System and Stent Success in the absence of death, emergency endarterectomy, repeat percutaneous transluminal angioplasty (PTA)/thrombolysis of the target vessel, stroke, or myocardial infarction (MI), as determined by the Clinical Events Committee (CEC).

  5. Patency at 30 Days [ Time Frame: Treatment through 30-day visit window ]
    Number of participants with less than 50% restenosis as determined by carotid duplex ultrasound core laboratory at 30 days post-procedure.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Carotid stenosis requiring revascularization and indicating either symptomatic status, with carotid stenosis ≥ 50% OR asymptomatic status with carotid stenosis ≥ 80%
  • Target lesion is located in one of the following:(a) internal carotid artery (ICA) (b) bifurcation (c) common carotid artery (CCA) proximal to the bifurcation
  • At Anatomic risk for adverse events from CEA (e.g. restenosis after a prior CEA) OR at Co-morbid risk for adverse events from CEA (e.g., unstable angina with ECG changes)

Exclusion Criteria:

  • Recent surgical procedure within 30 days before or after the stent procedure
  • Uncontrolled sensitivity to contrast media
  • Renal Insufficiency
  • Recent evolving, acute stroke within 21 days of study evaluation
  • Myocardial infarction within 72 hours prior to stent procedure
  • History of a prior major ipsilateral stroke with residual neurological deficits likely to confound the neurological assessments (e.g., NIHSS)
  • Neurological deficits not due to stroke likely to confound the neurological assessments (e.g., NIHSS)

Angiographic Exclusion Criteria:

  • Isolated ipsilateral hemisphere leading to subject intolerance to reverse flow
  • Total occlusion of the ipsilateral carotid artery
  • Pre-existing stent in the ipsilateral carotid artery OR the contralateral carotid artery that extends into the aortic arch
  • Presence of a filling defect, thrombus, occlusion or "string sign" in the target vessel
  • Severe lesion calcification restricting stent deployment
  • Carotid stenosis located distal to target stenosis that is more severe than target stenosis
  • > 50% stenosis of the CCA proximal to target vessel
  • Known mobile plaque in the aortic arch

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00594100

Layout table for location information
United States, New York
Millard Fillmore Gates/Univ. of Buffalo
Buffalo, New York, United States, 14209
United States, Ohio
Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195
Sponsors and Collaborators
W.L.Gore & Associates
Layout table for investigator information
Principal Investigator: Daniel Clair, M.D. The Cleveland Clinic
Principal Investigator: L. N. Hopkins, M.D. Millard Fillmore Gates/Univ. of Buffalo
Layout table for additonal information
Responsible Party: W.L.Gore & Associates Identifier: NCT00594100    
Other Study ID Numbers: NPS 05-05
First Posted: January 15, 2008    Key Record Dates
Results First Posted: May 5, 2009
Last Update Posted: December 27, 2013
Last Verified: December 2013
Keywords provided by W.L.Gore & Associates:
carotid artery stenosis
embolic protection device
GORE Neuro Protection System
GORE Flow Reversal System
reverse flow
proximal occlusion device
distal embolization
minimizing risks of CAS
Additional relevant MeSH terms:
Layout table for MeSH terms
Carotid Stenosis
Carotid Artery Diseases
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases